HAL (France)
open access
Engineering the subcutaneous delivery of antibody-drug conjugates
Subcutaneous (SC) delivery has evolved beyond a convenience formulation to become an operational rearchitecture of cancer care, with the potential to convert infusion-centered oncology into a distributed model without compromising exposure, safety, or product quality. Monoclonal antibodies have alre
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Subcutaneous administration of antibody-drug conjugates: current challenges, emerging opportunities, and future perspectives.#452916
- From Payload‐First Toward Dual‐Mechanism Antibody–Drug Conjugates#922939
- The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates#273690
- Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours#1085611
- Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming.#269472
Record · ID 971257
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive